FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387360790> ?p ?o ?g. }

• W4387360790 abstract "Abstract Disclosure: M. Kanin: None. M. Lechner: None. Introduction: Osteogenesis imperfecta (OI) is a rare inherited skeletal dysplasia characterized by bone fragility and skeletal malformation predisposing patients to multiple, recurrent fractures. Treatment of OI is challenging and requires a multidisciplinary approach with emphasis on physical therapy and exercise in addition to medications. There is limited guidance on treatment in adults given truncated life expectancy. Furthermore, guidance on the treatment of OI in the setting of cancer bone metastases is lacking. We present the unique case of a woman with OI and new fracture in the setting of bone-metastatic endometrial cancer. Clinical Case: A 70 year old woman with Type I OI and endometrial adenocarcinoma initially presented to clinic with left hip and groin pain. Prior OI therapy included at least 10 years of bisphosphonate therapy and 3 years of intranasal calcitonin in her fifties. CT imaging revealed a lytic lesion in the L inferior pubic ramus with an associated pathologic fracture. She was treated with denosumab 120mg s.c. every 3 months for six total doses and palliative radiation to the pubic ramus. She developed osteonecrosis of the jaw and further treatment was terminated. She represented 2 years later with right hip pain and was found to have cancer involvement of her right iliac bone. Labs showed creatinine of 0.48 mg/dL, Calcium 9.8 mg/dl, bone specific alkaline phosphatase 17.9ug/L (7.0-22.4 ug/L), n-telopeptide 18.6 nM BCE (6.2-19.0 nM BCE), and vitamin D-25 48ng/ml. DEXA scan showed T scores at the AP spine of -3.2, LFN of -2.1, and RFN of -2.5. Our patient had a high functional status, minimal pain and acceptable quality of life. Given the presence of active bone metastases, we favored treatment with zolendronic acid 4mg i.v. monthly given her high fracture risk, combined with continued cancer therapy targeted to bone metastases. Clinical Lesson: To our knowledge, there are no guidelines or case reports for optimal treatment of patients with concurrent OI and bone metastases. While bisphosphonates are typically a first line treatment for OI, osteoporosis and metastatic bone disease, the duration and dosing of bisphosphonates varies for each condition. For example, zolendronic acid 4mg i.v. monthly is recommended for cancer patients with metastatic bone disease, while a dose of 5mg i.v. yearly is used for osteoporosis, depending on the severity. Additionally, no clear consensus exists for how often or how long bisphosphonates may be given in adults with OI and treatment durations vary markedly. Other agents that may be considered include denosumab, with indications across bone metastases, osteoporosis, and OI, though this was not available to our patient given her prior complication. Data for newer agents PTH analogs and romosuzumab are lacking. We present this case to highlight the need for an individualized treatment approach in these patients. Presentation: Thursday, June 15, 2023" @default.
• W4387360790 created "2023-10-06" @default.
• W4387360790 creator A5004614055 @default.
• W4387360790 creator A5077912416 @default.
• W4387360790 date "2023-10-01" @default.
• W4387360790 modified "2023-10-06" @default.
• W4387360790 title "THU456 Beyond Guidelines: Treatment Of Concurrent Osteogenesis Imperfecta And Metastatic Bone Disease" @default.
• W4387360790 doi "https://doi.org/10.1210/jendso/bvad114.417" @default.
• W4387360790 hasPublicationYear "2023" @default.
• W4387360790 type Work @default.
• W4387360790 citedByCount "0" @default.
• W4387360790 crossrefType "journal-article" @default.
• W4387360790 hasAuthorship W4387360790A5004614055 @default.
• W4387360790 hasAuthorship W4387360790A5077912416 @default.
• W4387360790 hasBestOaLocation W43873607901 @default.
• W4387360790 hasConcept C126322002 @default.
• W4387360790 hasConcept C126894567 @default.
• W4387360790 hasConcept C141071460 @default.
• W4387360790 hasConcept C142724271 @default.
• W4387360790 hasConcept C2776139714 @default.
• W4387360790 hasConcept C2776286101 @default.
• W4387360790 hasConcept C2776326535 @default.
• W4387360790 hasConcept C2776541429 @default.
• W4387360790 hasConcept C2777251235 @default.
• W4387360790 hasConcept C2777668750 @default.
• W4387360790 hasConcept C2910508087 @default.
• W4387360790 hasConcept C71924100 @default.
• W4387360790 hasConceptScore W4387360790C126322002 @default.
• W4387360790 hasConceptScore W4387360790C126894567 @default.
• W4387360790 hasConceptScore W4387360790C141071460 @default.
• W4387360790 hasConceptScore W4387360790C142724271 @default.
• W4387360790 hasConceptScore W4387360790C2776139714 @default.
• W4387360790 hasConceptScore W4387360790C2776286101 @default.
• W4387360790 hasConceptScore W4387360790C2776326535 @default.
• W4387360790 hasConceptScore W4387360790C2776541429 @default.
• W4387360790 hasConceptScore W4387360790C2777251235 @default.
• W4387360790 hasConceptScore W4387360790C2777668750 @default.
• W4387360790 hasConceptScore W4387360790C2910508087 @default.
• W4387360790 hasConceptScore W4387360790C71924100 @default.
• W4387360790 hasIssue "Supplement_1" @default.
• W4387360790 hasLocation W43873607901 @default.
• W4387360790 hasOpenAccess W4387360790 @default.
• W4387360790 hasPrimaryLocation W43873607901 @default.
• W4387360790 hasRelatedWork W1976617516 @default.
• W4387360790 hasRelatedWork W2068020332 @default.
• W4387360790 hasRelatedWork W2463796064 @default.
• W4387360790 hasRelatedWork W2914708579 @default.
• W4387360790 hasRelatedWork W2970661456 @default.
• W4387360790 hasRelatedWork W3129184317 @default.
• W4387360790 hasRelatedWork W4288059207 @default.
• W4387360790 hasRelatedWork W4323304638 @default.
• W4387360790 hasRelatedWork W4210386494 @default.
• W4387360790 hasRelatedWork W4226239046 @default.
• W4387360790 hasVolume "7" @default.
• W4387360790 isParatext "false" @default.
• W4387360790 isRetracted "false" @default.
• W4387360790 workType "article" @default.